Pharmaceutical Isolator Global Market Report 2024

The pharmaceutical isolator market size has grown strongly in recent years. It will grow from $8.87 billion in 2023 to $9.57 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth observed in the historical period can be attributed to various factors, including stringent regulatory standards, a heightened focus on contamination control, increased demand for sterile products, a rise in biopharmaceutical production, and the growing adoption of aseptic processing in the pharmaceutical industry.

The pharmaceutical isolator market size is expected to see strong growth in the next few years. It will grow to $13.11 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period can be attributed to factors such as the global increase in pharmaceutical manufacturing, the expanding biotechnology sector, a rising focus on personalized medicine, continuous growth in regulatory scrutiny, and an increased emphasis on operator safety in pharmaceutical isolator applications. Notable trends expected in the forecast period encompass a market emphasis on ergonomic design and user-friendly features in isolators, the adoption of restricted access barrier systems (RABS), a focus on contamination control in sterility testing isolators, and collaborations for integrated isolator solutions.

The pharmaceutical isolator market is anticipated to experience growth due to the continuous expansion of the pharmaceutical sector. This industry involves public and commercial organizations engaged in discovering, developing, and manufacturing pharmaceuticals. Isolators in pharmaceutical manufacturing sites provide a secure environment, free from live bacteria, containing procedures and preventing contamination migration. This level of confinement surpasses standard clean rooms. For example, as per July 2022 data from the National Library of Medicine, overall pharmaceutical spending in the United States rose by 7.7% from 2020 to reach $576.9 billion in 2021. Projected increases in prescription drug spending for 2022 are estimated between 4.0% to 6.0%, further emphasizing the pharmaceutical sector's continuous growth, driving the pharmaceutical isolator market.

The pharmaceutical isolator market is also propelled by the growing aging population. This demographic, typically aged 65 or older, experiences a higher prevalence of chronic diseases requiring ongoing medical treatment. Pharmaceutical isolators play a crucial role in maintaining sterile and controlled environments during manufacturing processes, ensuring the safety and efficacy of medications for this demographic. According to October 2022 data from the World Health Organization, the population aged 60 or older is expected to grow from 1 billion in 2020 to 1.4 billion in 2030, contributing significantly to the pharmaceutical isolator market's growth.

A key trend in the pharmaceutical isolator market is product innovation. Major companies are focusing on new product developments to maintain their market position. For instance, ILC Dover introduced soloPURE in April 2021, a single-use flexible isolator for pharmaceutical and biopharmaceutical processing. This cost-effective isolator provides a closed, Grade-A, aseptic environment for fill-finish activities, addressing facility constraints and offering a more efficient solution compared to traditional closed-barrier systems.

Companies operating in the pharmaceutical isolator market are concentrating on developing products for sterility testing, aiming to enhance efficiency in this critical process. AUSTAR launched the Sterility Test Isolator Workstation (STIW) in March 2022, designed to create a risk-free environment for sterility testing, shielding it from outside contamination. The STIW ensures timely processing of loads and facilitates bio-decontamination of the airlock while the operator works in the main chamber, optimizing sterility testing efficiency.

In February 2021, Cytiva acquired Vanrx Pharmasystems to strengthen its position in aseptic filling and manufacturing solutions. Vanrx Pharmasystems, based in Canada, specializes in manufacturing automated aseptic filling machines, including closed and gloveless isolators. This acquisition is expected to contribute meaningful solutions to biomanufacturers, further solidifying Cytiva's presence in the pharmaceutical isolator market.

Major companies operating in the pharmaceutical isolator market report are Getinge AB, Wabash National Corporation, Chiyoda Corporation, Azbil Corporation, Hosokawa micron Ltd., Bioquell Limited, M Braun Inertgas-Systeme GmbH, Fedegari Group, Extract Technology Ltd., Germfree Laboratories Inc., COMECER SpA, Hosokawa Micron Powder Systems, ACIC Pharmaceutical Machinery, Skan AG, Custom Powder Systems, NuAire Limited, Gelman Singapore Pte Ltd., Contained Air Solutions Ltd., Dec Group, ITECO Engineering Srl, Schematic Engineering Industries Private Limited., Containment Technologies Group Inc., Inert Corporation.

North America was the largest region in the pharmaceutical isolator market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical isolator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical isolator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of pharmaceutical isolators are closed isolator systems and open isolator systems. Closed isolator systems are specialized containment systems utilized in pharmaceutical manufacturing and compounding settings. They provide a safe and regulated environment for various pharmaceutical processes, including aseptic production and sterile compounding, ensuring product quality and operational safety. Different configurations, such as floor-standing, modular, mobile, compact, tabletop, and portable, are applied in aseptic isolators, containment isolators, and other applications. Pharmaceutical isolators are used in various end-users, including pharmaceutical and biotechnology companies, research laboratories, and others.

The pharmaceutical isolator market research report is one of a series of new reports that provides pharmaceutical isolator market statistics, including pharmaceutical isolator industry global market size, regional shares, competitors with a pharmaceutical isolator market share, detailed pharmaceutical isolator market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical isolator industry. This pharmaceutical isolator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pharmaceutical isolators market consists of sales of class III BSC-configured isolators, compounding aseptic isolators (CAI), compounding aseptic containment isolators (CACI), cell processing isolators (CPI), formulation and filling line isolators and bio isolators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.